Showing posts with label RNA. Show all posts
Showing posts with label RNA. Show all posts
Monday, September 23, 2024

IN treating Cancerous tumors, TransCode's technology is designed to target dysregulated microRNAs implicated in cancer progression, metastasis, and resistance to existing therapies.

›
  Investor Report: TransCode Therapeutics Inc. (NASDAQ: RNAZ) Introduction TransCode Therapeutics Inc. is a clinical-stage biopharmaceutical...
Tuesday, June 18, 2024

Acquisitions in Biotech and SynBio stocks are on the horizon again and here is one that we believe may be in the crosshairs!

›
 Ginkgo Bioworks operates several advanced biotechnology platforms and technologies that would be particularly attractive to an acquiring co...
Tuesday, May 28, 2024

Ginkgo Bioworks has been bolstering its position as a first mover in Synthetic Biology!

›
  .  Here are the companies they’ve acquired and the reasons behind each acquisition: Proof Diagnostics : -  Ginkgo Bioworks acquired Proof ...
Saturday, May 11, 2024

The Human body is highly "Adaptive" in fighting desease, and these two companies are developing technology right now to help that system fight Cancer!

›
  Let’s compare   Adaptive BioTechnologies   and   Agenus Inc .   in terms of how they utilize the adaptive immune system to combat cancer: ...
Wednesday, May 1, 2024

Ginkgo Bioworks is building out their BioManufacturing Foundry platform which mimics the building of semiconductor foundries of yester year!

›
  78.63% of #GinkgoBioworks ( $DNA ) stock is owned by #Institutional #investors . Here are some of the major institutional shareholders: ...
1 comment: